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Abstract 
Insights into the molecular pathogenesis of glioblastoma have not yet resulted in relevant 
clinical improvement. With standard therapy, consisting of surgical resection with 
concomitant temozolomide in addition to radiotherapy followed by adjuvant temozolomide, 
median survival is 12–14 months. Therefore, the identification of novel molecular targets and 
inhibitory agents has become a focus of research for glioblastoma treatment. Recent results 
with bevacizumab may represent a proof of principle that treatment with targeted agents can 
result in clinical benefits for patients with glioblastoma. This review discusses limitations in 
the existing therapy for glioblastoma and provides an overview of current efforts to identify 
molecular targets using large-scale screening of glioblastoma cell lines and tumor samples. 
Preclinical and clinical data for several novel molecular targets including growth factor 
receptors, phosphatidylinositol-3 kinase, SRC-family kinases, integrins, and CD95 ligand 
and agents that inhibit these targets, including erlotinib, enzastaurin, dasatinib, sorafenib, 
cilengitide, AMG102, and APG101 are discussed. By combining advances in tumor 
screening with novel targeted therapies, it is hoped that new treatment options will emerge 
for this challenging tumor type. 
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Introduction 
Glioblastoma is the most common primary central nervous system tumor, accounting for 
approximately 60% of 17,000 primary brain tumors diagnosed annually in the US.1 Patients 
diagnosed with glioblastoma have a dismal prognosis, typically dying within 3 months if 
untreated. Standard treatment increases median survival to 12 months, although disease 
tends to progress within 6–9 months and the 2-year survival rate is less than 25%.2 In this 
review, we discuss the limitations of existing therapies for glioblastoma, before summarizing 
ongoing efforts to identify novel molecular targets and develop novel targeted agents for this 
disease. 
 
Search Strategy and Selection Criteria 
Relevant publications in the PubMed database published between January 1995 and 
February 2010 were identified using the search terms “glioblastoma”, “glioma”, “VEGF”, 
“EGFR”, “PI3K”, “SRC”, “PDGFR”, “integrin”, “CD95”, “TRAIL”, and “c-MET”. Only papers 
published in English were reviewed. Relevant clinical trials were identified by searching 
http://www.clinicaltrials.gov/ using the search terms “glioblastoma” and “glioma”. 
 
Current Glioblastoma Therapy  
The current standard of care for newly diagnosed glioblastoma is surgical resection with 
concomitant daily temozolomide (TMZ; 75 mg/m2) and radiotherapy, followed by six cycles 
of adjuvant TMZ (150–200 mg/m2) for 5 days during each 28-day cycle.3 However, almost all 
patients with glioblastoma experience disease recurrence. Because no standard treatment 
option exists following recurrence, rechallenging with TMZ or switching to an alternative TMZ 
dosing regimen has become common practice. In a retrospective analysis (N = 80), 6-month 
progression-free survival (PFS) was similar in patients with recurrent glioblastoma or 
anaplastic astrocytoma following TMZ regimen change (26%) or rechallenge (29%).4 The 
Canadian RESCUE study showed similar results using a low-dose metronomic TMZ 
schedule, reporting a smaller benefit from rechallenge if prior TMZ exposure exceeded 6 
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months.5 Ongoing studies are investigating alternative TMZ regimens in first-line and 
second-line settings, including the Neurooncology Working Group (NOA)-08, Radiation 
Therapy Oncology Group (RTOG) 0525, and DIRECTOR trials.  
 
Targeted Therapy for Glioblastoma 
The introduction of molecularly targeted agents is one of the most significant advances in 
cancer therapy in recent years. Targeted therapies block activation of oncogenic pathways, 
either at the ligand–receptor interaction level or by inhibiting downstream signal transduction 
pathways, thereby inhibiting growth and progression of cancer. Because of their specificity, 
targeted therapies should theoretically have better efficacy and safety profiles than systemic 
cytotoxic chemotherapy or radiotherapy. 
 Because of the substantial neovascularization seen in glioblastoma, targeted 
antiangiogenic therapies have received considerable attention.6 The main rationale for using 
antiangiogenic therapies in glioblastoma is to normalize the vasculature, restoring the 
selective permeability of the blood-brain barrier (BBB), rather than starving tumors of oxygen 
and growth factors as originally proposed.7 However, animal models of glioblastoma have 
shown that antiangiogenic therapies may reduce the effectiveness of TMZ.8 The sequence 
of combination regimens and effects of specific antiangiogenic therapies on the BBB should 
be fully characterized to optimize therapy. 
 Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth 
factor (VEGF), has shown unusually high response rates in recurrent grade 3 and 4 gliomas 
(6-month PFS = 46%, 6-month overall survival (OS) = 77%),9 which led to US approval for 
glioblastoma. Whether these response rates are a valid surrogate for PFS and OS remains a 
matter of debate.10 Recently, the worry of more distant recurrences with bevacizumab 
treatment was not substantiated in a matched-pair analysis.11    
 
Identifying Novel Therapeutic Targets in Glioblastoma 
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Identifying biological mechanisms contributing to glioblastoma oncogenesis will help 
researchers and physicians to develop and select appropriate targeted therapies to improve 
patient outcomes. In a large-scale multidimensional analysis carried out by the Cancer 
Genome Atlas in 206 glioblastoma samples, 91 of which were also analyzed to identify 
nucleotide sequence aberrations, the most frequent gene amplifications were: epidermal 
growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR)α, two 
transmembrane receptors with tyrosine kinase activity; cyclin-dependent kinase 4 (CDK4), a 
promoter of cell cycle progression; and murine double minute (MDM)2 and MDM4, 
suppressors of P53 activity.12 The most frequent homozygous gene deletions were: 
CDKN2A, CDKN2B, and CDKN2C, which encode tumor suppressor proteins that suppress 
activation of CDK4 and CDK6; phosphatase and tensin homolog (PTEN), a tumor 
suppressor that inhibits phosphatidylinositol-3 kinase (PI3K) signaling; retinoblastoma (RB1), 
a cell cycle inhibitor; PARK2, a regulator of dopaminergic cell death; and neurofibromin 
(NF)1, a negative regulator of the RAS signal transduction pathway. The most frequently 
mutated genes were: P53; PTEN; NF1; EGFR; human epidermal growth factor receptor 2 
(HER2); RB1; and PIK3R1 and PIK3CA, two components/regulators of the PI3K signaling 
pathway. This study shows that signaling pathways involving receptor tyrosine kinases/PI3K, 
regulators of the cell cycle such as P53 and the cyclin/RB1 pathway are considerably altered 
in glioblastoma (Fig. 1). 
 A similar study has identified characteristic mutations in the active site of isocitrate 
dehydrogenase 1 (IDH1) in 12% of glioblastoma patients. IDH1 mutations occurred in a high 
proportion of young patients and in the majority of secondary glioblastoma cases and were 
associated with increased OS (3.8 years) compared with wild-type IDH1 (1.1 years).13 This 
may be due to increased tumor sensitivity to chemotherapy,14 although a large controlled 
series of the German Glioma Network did not find any association between prolonged 
survival of patients with tumors with IDH1 mutations and administration of a specific 
therapy.15 Mutation of the IDH1 active site prevents conversion of isocitrate to α-
ketoglutarate but allows the mutated enzyme to catalyze the nicotinamide dinucleotide 
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phosphate-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG). 
Accumulated 2HG appears to act as an oncometabolite that contributes to glioma formation 
and malignant progression. This observation is supported by data from patients with 
inherited 2-hydroxyglutaric aciduria in whom deficient 2HG dehydrogenase causes an 
accumulation of brain 2HG. These patients have an increased risk of developing brain 
tumors, possibly because of increased production of reactive oxygen species.16 
 Increased tyrosine kinase activity has also been associated with glioblastoma 
oncogenesis. In a tyrosine kinase activation catalog covering 130 human cancer cell lines, 
the most frequently activated tyrosine kinases were: EGFR; fibroblast growth factor receptor 
3 (FGFR3); protein tyrosine kinase 2 (PTK2, also known as focal adhesion kinase, or FAK); 
and SRC, LCK, and LYN, three members of the SRC-family kinases (SFK).17 SRC and SFKs 
mediate downstream signaling from several growth factor receptors and SRC is a key 
binding partner of FAK.18 Screening of 31 primary glioblastoma samples showed similar 
patterns of tyrosine kinase activation, including SRC activation in 61% of the samples.17 
Overexpression of SFKs has been reported in previous studies,19 although the Cancer 
Genome Atlas study did not identify any focal amplification or somatic missense mutations of 
SRC or SFKs.12  
 Studies have already been performed using novel agents that inhibit targets identified 
by screening methods discussed above, or based on preclinical studies and experience in 
other tumors (Table 1). However, further analyses of clinical and molecular data derived 
from these trials (Table 2)20-44 are necessary to verify the relevance of these targets to 
glioblastoma. 
 
Therapeutic Inhibition of Novel Molecular Targets in Glioblastoma 
VEGF Signaling 
Approval of the anti-VEGF antibody bevacizumab for glioblastoma has highlighted the 
potential for other antiangiogenic agents in glioblastoma therapy (Fig. 2). Cediranib is a 
potent, orally available, small-molecule inhibitor of VEGF-receptor (VEGFR) tyrosine kinase 
 9 
activity that rapidly normalizes tumor blood vessels in patients with glioblastoma, leading to a 
clinical improvement in cerebral edema.47 In mouse models, improvement in edema was 
associated with increased survival despite continued tumor growth.48 The first clinical data of 
the REGAL trial of cediranib plus lomustine (CCNU) to investigate whether preclinical 
findings will translate into improvements for patients with recurrent glioma have been 
negative.49 Six other clinical trials are underway to assess cediranib as either a monotherapy 
or in combination with other agents (Table 3). 
 
Epidermal Growth Factor Receptor Family 
Approximately 50% of glioblastomas overexpress EGFR and 25% express a constitutively 
active mutated form of EGFR.50 EGFR overexpression and immunoreactivity are more 
common in primary tumors than in secondary glioblastomas.51 These observations, in 
addition to the large body of preclinical data in glioblastoma52 and successful targeting of 
EGFR in other tumors, make EGFR an attractive target for glioblastoma therapy. However, 
caution is needed with EGFR inhibitors because hypoxia and low glucose levels might 
convert the cytotoxic effects of EGFR inhibition into a cytoprotective effect.53 
 One agent that has been the subject of many clinical trials is erlotinib, an orally active 
inhibitor of the EGFR tyrosine kinase approved for treating some forms of nonsmall cell lung 
cancer (NSCLC) and pancreatic cancer. In a phase I study, patients with gliomas expressing 
high levels of EGFR and low levels of activated AKT had better responses to erlotinib (50% 
decrease in tumor cross-sectional area, than those with low EGFR expression and high 
levels of activated AKT.54 However, phase II trials have so far shown limited clinical benefit 
of erlotinib in patients with either recurrent or newly diagnosed glioblastoma (Table 2), either 
in combination regimens22, 23, 33, 34 or as monotherapy.31 Studies to identify markers predicting 
response to EGFR inhibitors in patients with recurrent glioblastoma have shown significant 
correlation of response to therapy with coexpression of the PTEN tumor suppressor and the 
EGFR deletion mutant variant III (EGFRvIII) (P < .001; odds ratio, 51; 95% confidence 
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interval (CI), 4–669).55 However, this has been suggested to be a prognostic phenomenon.31 
Ongoing clinical trials of erlotinib and other EGFR-directed drugs are summarized in Table 3. 
 
Phosphatidylinositol-3 Kinase and Related Pathways 
PI3K plays a role in intracellular signaling pathways regulating cell survival, growth, and 
proliferation. Activated PI3K is recruited to the cell membrane where it mediates signaling 
following receptor activation. Downstream signaling proteins include: AKT, a promoter of 
growth, proliferation, and survival; glycogen synthase kinase-3 (GSK-3), a regulator of c-
MYC and cyclin degradation; and mammalian target of rapamycin (mTOR), a regulator of 
protein synthesis and negative regulator of PI3K.56 
 Regulators of PI3K signaling are frequently mutated in glioblastomas and preclinical 
studies suggest that inhibiting the PI3K pathway may have therapeutic potential.12 NVP-
BEZ235, an orally available kinase inhibitor of PDK1, mTOR, and PI3K, induced G1 arrest of 
a glioblastoma cell line in vitro, and enhanced TMZ efficacy in vivo.57 Glioblastoma cells 
treated with LY294002, a specific PI3K inhibitor, became sensitized to chemotherapy-
induced apoptosis.58 These preclinical studies suggest that PI3K inhibitors have the potential 
to overcome TMZ resistance in recurrent glioblastoma. NVP-BEZ235 treatment is currently 
in phase I trials in patients with solid tumors (Table 3). 
 Enzastaurin, a PKC/PI3K/AKT inhibitor, suppressed proliferation and induced 
apoptosis via a caspase-dependent mechanism in glioblastoma cells in vitro59 and inhibited 
growth of human glioblastoma xenografts, accompanied by decreased phosphorylation of 
downstream signaling molecules, including GSK-3β.60 In vivo models showed that  
enzastaurin combined with radiotherapy synergistically reduced tumor volume, radiation-
induced satellite tumor formation, upregulation of VEGF expression, neovascularization, and 
GSK-3β phosphorylation.61 In a phase II study of enzastaurin in patients with recurrent 
heavily pretreated glioblastoma, an interim analysis showed that objective radiographic 
responses occurred in approximately 20% of patients.62 The subsequent phase III trial 
comparing lomustine and enzastaurin at first or second recurrence was the first phase III trial 
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to evaluate a targeted therapy for recurrent glioblastoma. However, a planned interim 
analysis found that enzastaurin treatment did not significantly increase PFS, leading to 
enrolment being halted. The final analysis confirmed the absence of any significant 
difference across all efficacy endpoints (Table 2).29 
 Whilst ineffective in glioblastoma, enzastaurin monotherapy appears to have poor 
tolerability (thrombocytopenia and prolonged QTc as dose-limiting toxicities) and limited 
efficacy in patients with malignant glioma as shown by over 150 weeks of PFS in 2 
patients.63 In a phase I/II trial, enzastaurin had limited efficacy in patients with anaplastic 
glioma (6-month PFS = 16%) and negligible efficacy in patients with glioblastoma (6-month 
PFS = 7%).28 
 
SRC and SRC-family Kinases 
SRC and SFKs are frequently activated in glioblastoma cell lines and patient samples,17 and 
SFK overexpression has also been reported,19 although not in the Cancer Genome Atlas 
study.12 SRC and SFKs are promiscuous regulators of multiple signaling pathways 
regulating cell growth, proliferation, adhesion, migration, and invasion, which are important 
processes in tumor invasion and metastasis. In particular, SFKs mediate signaling from 
growth factor receptors commonly overexpressed in glioblastomas, providing a potential 
mechanism for SFK activation. Recently, SRC and FYN (a SFK) were shown to mediate 
oncogenic EGFR and EGFRvIII signaling in a rodent glioblastoma model.19 SRC inhibition 
also reduced glioblastoma cell viability and migration in vitro and decreased growth in vivo.17 
Transgenic mice expressing v-SRC, a viral oncogenic homolog of cellular SRC, develop 
brain tumors that rapidly progress to mimic the morphological and molecular characteristics 
of human glioblastoma, providing additional strong evidence that SFKs may be a promising 
target for glioblastoma therapy.64 
 Dasatinib is a potent inhibitor of SRC and SFK tyrosine kinase activity and is 
approved for treatment of certain types of leukemia based on activity against BCR-ABL.65 
Dasatinib also has inhibitory activity against c-KIT and PDGFR.66 In glioblastoma cells, 
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dasatinib inhibited migration and induced autophagic cell death, and autophagy was 
increased by combining dasatinib with TMZ.19, 67 In vivo, dasatinib inhibited invasion, 
promoted tumor regression, and induced apoptosis in EGFRvIII-expressing glioblastomas, 
and enhanced the activity of anti-EGFR antibodies.19 
Trials of dasatinib are ongoing in several solid tumors, including glioblastoma (Table 
3). A phase I/II trial in patients with newly diagnosed glioblastoma is assessing dasatinib 
combined with radiotherapy and concomitant TMZ followed by adjuvant dasatinib plus TMZ. 
Trials of dasatinib in recurrent glioblastoma include a phase II trial of dasatinib monotherapy, 
a phase I trial in combination with erlotinib, and a randomized phase I/II trial in combination 
with CCNU that has started its phase I part in patients with recurrent glioblastoma as part of 
an EORTC initiative (Table 3). 
 
Platelet-derived Growth Factor Receptor 
PDGFR is a receptor tyrosine kinase with  and  isoforms. Overexpression of PDGFR- 
has been demonstrated in all grades of astrocytoma, including in one in six glioblastomas,49 
indicating a potential role in tumor development.68 Several PDGFR-targeting agents have 
been developed that may have therapeutic potential against tumors with elevated PDGFR 
expression. 
 Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth 
and proliferation by blocking the action of intracellular and receptor kinases including 
PDGFR, RAF kinase, VEGFR2, and c-KIT.69 In human glioblastoma cell lines, sorafenib 
inhibited proliferation synergistically in combination with bortezomib, a proteosome 
inhibitor,70 and rottlerin, an experimental inhibitor of protein kinase C.71 A phase II trial found 
that first-line TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients 
with glioblastoma, although preliminary efficacy data for this regimen (median PFS = 6 
months, 12-month PFS = 16%) were similar to standard therapy (Table 2).24 Clinical trials of 
sorafenib are summarized in Tables 2 and 3. 
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 Preclinical trials of imatinib, a small-molecule inhibitor of PDGFR, ABL, and c-KIT, 
have shown growth inhibition in a subpopulation of CXCL12-expressing glioblastoma cells72 
and radiosensitizing activity.73 However, in phase II trials in recurrent glioblastoma, imatinib 
alone or combined with hydroxyurea had limited antitumor activity (Table 2).37-41 The 
combination of imatinib, hydroxyurea, and vatalanib, a VEGFR inhibitor, was well tolerated in 
a phase I trial and has been suggested as a possible multitargeted regimen for 
glioblastoma.36 Ongoing trials include a trial of imatinib and TMZ in patients with either newly 
diagnosed or recurrent glioblastoma and six trials in recurrent glioblastoma of imatinib 
monotherapy, or combined with TMZ or hydroxyurea (Table 3). 
 Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase 
activity. Although no preclinical data have been reported for tandutinib in glioblastoma, two 
early-phase trials are assessing tandutinib in recurrent or progressive glioblastoma as 
monotherapy or combined with bevacizumab (Table 3).  
 Although gene expression and preclinical data suggest that PDGFR may be a 
promising target for treating glioblastoma, the available clinical data suggest otherwise. Trial 
data are awaited from novel combination regimens involving PDGFR inhibitors. 
 
Integrins 
Integrins play key roles regulating cellular adhesion, migration, and invasion. In addition to a 
structural role, integrins also activate intracellular signaling proteins, including SRC. In 
various tumors, integrins have an established role in metastasis, and angiogenesis.74 
Therefore, targeting integrin function may have potential for treating glioblastoma.  
 Cilengitide is a specific αV integrin inhibitor in clinical development. In vitro, cilengitide 
blocked glioma cell adhesion without effecting tumor radiosensitivity, despite increasing 
radiation-induced vascular endothelial cell death. However, cilengitide combined with 
radiotherapy in vivo more than doubled survival time to over 110 days compared with 
radiotherapy alone (50 days survival).75 A second study showed inconsistent effects of 
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cilengitide on cell migration or invasiveness across several glioma cell lines, although 
additive effects were observed for cilengitide combined with TMZ.76  
 Cilengitide has been assessed in clinical trials (Table 2). In a phase I/IIa trial, 
cilengitide combined with the current standard of therapy in patients with newly diagnosed 
glioblastoma was well tolerated with an encouraging 6-month PFS of 69%. Tumor O6-
methylguanine-DNA methyltransferase (MGMT) promoter methylation predicted a higher 
likelihood of achieving 6-month PFS as shown by increases in PFS and OS to 13.4 months 
and 23.2 months, respectively, compared with 3.4 and 13.1 months in patients without 
MGMT promoter methylation.21 Based on these findings, a similar regimen is being 
compared with radiotherapy/TMZ alone in the phase III CENTRIC trial in patients with newly 
diagnosed glioblastoma whose tumors have a hypermethylated MGMT promoter (Table 3). 
In a phase IIa study in recurrent glioblastoma, cilengitide monotherapy was well tolerated but 
was largely inactive (6-month PFS = 15%): long-term disease stabilization was seen in a 
small subset of patients, 10% were progression-free for greater than 12 months and 5% 
were progression-free for greater than 24 months.27 
A recent preclinical study has suggested that integrin inhibitors may paradoxically 
stimulate tumor growth and angiogenesis when doses are missed.77 However, because of 
the artificial dosing schedule and nonglioma models used for preclinical investigations, this 
may not represent an issue for ongoing trials in glioblastoma.78 
 
c-MET Inhibitors 
Aberrant signaling by the MET receptors and its ligand, hepatocyte growth factor (HGF), has 
been observed in various tumors, including glioblastoma, and potential involvement in 
tumorigenesis and metastasis has been reported.79 In a recent study, c-MET overexpression 
was detected in 18/62 glioblastoma samples (29%) and patients with c-MET overexpression 
had shorter median survival than those with little or no c-MET expression (median survival 
11.7 months vs 14.3 months).80 
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Inhibitors of HGF or c-MET have shown preclinical activity against glioblastoma cell 
lines.79 The anti-HGF antibody AMG102 enhanced TMZ-induced inhibition of glioblastoma 
cell line growth in vitro and in xenografts81 and in an ongoing phase II trial in patients with 
recurrent glioblastoma AMG102 was well tolerated with initial evidence of response seen in 
a small proportion of patients (Table 2).26 PF02341066, an orally available ATP-competitive 
small-molecule inhibitor of c-MET that inhibited glioblastoma growth and cMET 
phosphorylation in preclinical studies,82 is under clinical investigation in patients with 
advanced cancers. 
 
Glutamate Receptor Inhibition 
Alpha-amino-3-hydroxy-5 methyl-4-isoxazolepropionate (AMPA) glutamate receptor 
antagonists have been used to prevent neurotoxicity in several nontumor neurologic 
disorders. Because glioblastomas secrete glutamate and preclinical evidence suggests a 
role of the glutamate/AMPA system in proliferation and migration, talampanel, an orally 
available BBB-permeable AMPA inhibitor, has been assessed in clinical trials. Initial phase 
I/II data for first-line talampanel combined with standard of care have suggested improved 
efficacy compared with recent historic controls demonstrated a median OS of 18.3 months 
(95% CI, 14.6–22.5 months).25 However, a phase II trial of talampanel monotherapy in 
patients with recurrent disease found no significant activity (6-month PFS was 4.6%, median 
PFS was 5.9 weeks, median OS was 13 weeks) (Table 2).44  
 
HDAC inhibition 
Histone deacetylases (HDAC) are involved in multiple processes shaping the malignant 
phenotype of glioma including maintanance of stemness, angiogenesis and resistance to 
DNA damage. Vorinostat (Zolinza™), an orally available inhibitor of class I and II HDAC 
approved for advance cutaneous T cell lymphoma. In a phase II study in recurrent 
glioblastoma vorinostat monotherapy was well tolerated and had modest clinical activity (6-
 16 
month PFS was 15.2%, median OS was 5.7 months.45 Vorinostat is currently being 
evaluated in newly diagnosed and recurrent glioblastoma as a combination therapy. 
 
Death-receptor targeting has been an experimental approach for malignant glioma for more 
than a decade.83 Death-receptor ligand activation can also have nonapoptotic effects, as 
demonstrated using anti-CD95 antibody treatment of mouse glioblastoma models.84 APG101 
is an inhibitor of CD95 ligand consisting of the CD95 receptor extracellular domain fused to 
the Fc domain of IgG. A randomized phase II trial of APG101 plus radiotherapy vs 
radiotherapy has recently been initiated in patients with recurrent glioblastoma. Future 
research will determine whether inducing apoptosis or relying on the nonapoptotic properties 
of death ligands will be advantageous for glioblastoma treatment. 
Poly [ADP-ribose] polymerase (PARP) is a DNA repair enzyme implicated in the resistance 
of tumors to DNA damaging anticancer agents and radiotherapy.85 Iniparib (BSI-201), which 
has recently demonstrated clinical efficacy in triple-negative breast cancer86, is currently 
being explored in a phase I/II study in patients with newly diagnosed glioblastoma. 
 
Discussion 
Targeted therapies have revolutionized oncology, causing a shift from systemic and/or slow-
release implants of cytotoxic drugs towards highly specific agents that are more selective at 
targeting tumor cells. Clinical studies with EGFR and PDGFR inhibitors as monotherapy, 
however, have so far failed to show any efficacy in glioblastoma. New data indicate that 
subtypes of glioblastoma exist with distinct molecular characteristics, suggesting that to fully 
evaluate targeted agents, patient selection based on tumor subtype may be needed. 
Because of the progressive nature of glioblastoma and the accumulation of genomic and 
proteomic changes, it is also possible that a recurrent tumor may have different 
characteristics from the primary tumor, suggesting that tumors should be rebiopsied at 
recurrence to ensure that an appropriate therapy is selected. Translation of promising 
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preclinical data into a clinically useful therapy remains challenging, with data frequently 
generating new questions or hypotheses that need to be addressed in the laboratory.  
 Targeted agents are likely to have greatest potential when used in combination to 
increase the activity of standard chemotherapies, broadening the range of pathways 
inhibited by treatment, and/or counteracting mechanisms of resistance. In addition, as for 
classic cytotoxic agents, an intact blood-brain-barrier may represent an important 
impediment limiting the efficacy of targeted therapies. Numerous trials are ongoing to 
investigate combinations of targeted therapies with other agents, potentially accompanied by 
novel methods of patient monitoring or assessment based on the mechanism of action, 
allowing for more individualized patient therapy. Dialog between preclinical and clinical 
research will allow us to address the questions or hypotheses arising from the use of novel 
therapies, leading to fine-tuning of clinical trial regimens and a better understanding of which 
patients may benefit from a particular therapy. Coupled with advances in tumor screening 
and outcome assessment, this will hopefully result in new treatment options and meaningful 
patient benefits. 
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Figure legends 
 
Fig. 1. Genetic alterations in glioblastoma signal transduction pathways (adapted from 
Parsons et al.)13 (A) Proliferation and survival signaling is altered in 88% of glioblastomas. 
(B) p53 signaling is altered in 87% of glioblastomas. (C) RB signaling is altered in 78% of 
glioblastomas. 
CCND2, cyclin-D2; CDK, cyclin-dependent kinase; CDKN, cyclin-dependent kinase inhibitor; 
EGFR, epidermal growth factor receptor; FOXO, forkhead box-O; HER2, human epidermal 
growth factor receptor-2; NF1, neurofibromin; PDGFR, platelet-derived growth factor 
receptor; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin homolog; RB1, 
retinoblastoma protein-1; SRC* = activated (phosphorylated) SRC. 
Fig. 1 is adapted from The Cancer Genome Atlas Research Network. Comprehensive 
genomic characterization defines human glioblastoma genes and core pathways. Nature 
2008;455(7216):1061–1068. 
 
Fig. 2. Molecular targets of antiangiogenic therapies investigated in glioblastoma. 
ANG, angiopoietin; CKII, casein kinase II; eNOS, endothelial nitric oxide synthase; ERK, 
extracellular signal-regulated kinases; FAK, focal adhesion kinase; GSK3β, glycogen 
synthase kinase 3β; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian 
target of rapamycin; PDGF(R), platelet-derived growth factor (receptor); PI3K, 
phosphatidylinositol 3-kinase; PKC, protein kinase C; PLCγ, phopholipase Cγ; VEGF(R), 
vascular endothelial growth factor (receptor). 
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Table 1. Targeted therapies in clinical trials for glioblastoma 
Agent Target 
molecules 
Approved 
cancer 
indications 
Combination treatments 
under investigation 
APG101 CD95 None RT 
AMG102 c-MET None Monotherapy 
Cetuximab EGFR CRC, HNSCC TMZ+RT 
Erlotinib EGFR NSCLC, 
pancreatic 
TMZ+RT 
CCNU 
Carboplatin 
Sorafenib 
Sirolimus 
Temsirolimus 
Bevacizumab 
Gefitinib EGFR NSCLC Monotherapy 
BIBW2992 EGFR, HER2 None Monotherapy 
TMZ 
TMZ+RT 
Lapatinib EGFR, HER2 MBC Monotherapy 
Pazopanib 
Cilengitide αV integrins None TMZ+RT 
Imatinib PDGFR CML, Ph+ ALL, 
KIT+GIST 
Vatalanib+hydroxyurea 
TMZ 
Hydroxyurea 
Tandutinib PDGFR None Monotherapy 
Bevacizumab 
 30 
NVP-BKM120  PI3K None Monotherapy 
Enzastaurin PKC/PI3K/AKT  None Monotherapy 
RT 
TMZ+RT 
Dasatinib SRC CML, Ph+ ALL Monotherapy 
TMZ 
TMZ+RT 
CCNU 
Erlotinib 
Bevacizumab VEGF CRC, MBC, 
GBM, RCC, 
NSCLC 
Cetuximab+irinotecan 
Cediranib VEGFR None Monotherapy 
TMZ 
CCNU 
Bevacizumab 
Cilengitide 
Vandetanib VEGFR, EGFR None Monotherapy 
TMZ 
Carboplatin 
Imatinib 
Sirolimus 
Etoposide 
Vorisnostat HDAC I/II T cell lymphoma Monotherapy 
TMZ 
Bevacizumab 
Irinotecan 
 31 
Bortezomib 
Sorafenib VEGFR, 
PDGFR, MAPK 
RCC, HCC Monotherapy 
TMZ+RT  
TMZ 
Temsirolimus 
Erlotinib 
Bevacizumab 
 
 
CCNU, lomustine; CML, chronic myeloid leukemia; CRC, colorectal carcinoma; EGFR, 
epidermal growth factor receptor; GBM, glioblastoma multiforme; HCC, hepatocellular 
carcinoma; HDAC, histone deacetylase; HER2, human epidermal growth factor receptor 2; 
HNSCC, head and neck squamous cell carcinoma; MAPK, mitogen-activated protein kinase 
signaling; MBC, metastatic breast cancer; NSCLC, nonsmall cell lung carcinoma; PDGFR, 
platelet-derived growth factor receptor; Ph+ ALL, Philadelphia chromosome-positive acute 
lymphoblastic leukemia; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; RCC, 
renal cell carcinoma; RT, radiotherapy; TMZ, temozolomide; VEGFR, vascular endothelial 
growth factor (receptor). 
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Table 2. Published clinical data for targeted therapies in glioblastoma 
Agents Phase Primary/recurrent 
disease 
Patients 
(n) 
Primary outcomes Positive prognostic 
indicator(s) 
Reference
Cetuximab+TMZ+RT I/II Primary 39 12-month OS = 89%, 24-month OS = 
42%, 6-month PFS = 76%, 12-month 
PFS = 45% 
EGFR and PTEN 
coexpression 
significantly 
correlated with PFS 
(P = .005) 
20 
Cilengitide+TMZ+RT I/IIa Primary 52 6-month PFS = 69% MGMT promoter 
methylation 
21 
Erlotinib+TMZ+RT I/II Primary 97 OS = 15.3 months 
median PFS = 7.2 months 
None 22 
Erlotinib+TMZ+RT II Primary 65 Median OS = 19.3 months 
median PFS = 8.2 months 
MGMT promoter 
methylation and 
PTEN+ (P = .04) 
23 
 33
RT+TMZ 
TMZ+sorafenib 
II Primary 47 Median PFS = 6 months (95% CI 3.7 
to 7.0 months) 
12-month PFS = 16% 
NA 24 
Talampanel II Primary 72 OS = 18.3 months (median) NR 25 
AMG102 II Recurrent 20 Response rate by Macdonald criteria:  
one cPR, two SD, 14 PD, 
one minor response 
NA 26 
Cediranib +/- CCNU III Recurrent 300 PFS Cediranib 30 mg = 3 months 
 Cediranib 20 mg + CCNU = 4 
 months 
 CCNU = 2.7 months  
NA 47 
Cilengitide IIa Recurrent 81 6-month PFS = 16% NA 27 
Enzastaurin II Recurrent 85 Objective radiographic responses in 
14 patients (10 GBM), including one 
CR 
6-month PFS = 7% 
NA 28 
 34
Enzastaurin III Recurrent 266 No significant effect on PFS (1.5 vs 
1.6 months), OS (6.6 vs 7.1 months), 
6-month PFS (P = .13), SD (38.5 vs 
35.9%), or OR (2.9 vs 4.3%) 
respectively for enzastaurin vs 
lomustine 
NA 29 
Erlotinib+ 
temsirolimus 
I/II Recurrent 22 (phI)  
56 (phII) 
6-month PFS = 12.5% NR 30 
Erlotinib+ 
TMZ/CCNU 
II Recurrent 110 6-month PFS = 11.4% Low phospho-AKT  
(P = .068) 
31 
Erlotinib+ 
bevacizumab 
II Recurrent 24 (MG) 
32 (AG) 
6-month PFS = 25% NR 32 
Erlotinib+ 
carboplatin 
II Recurrent 43 Median PFS = 9 weeks, 6-month PFS 
= 14% 
None 33 
Erlotinib+sirolimus II Recurrent 32 6-month PFS = 3.1% Increased phospho-
AKT (P = .045) 
34 
Gefitinib II Recurrent 28 6-month PFS = 14.3% None 35 
 35
Imatinib+vatalanib+ 
hydroxyurea 
I Recurrent 37 Vatalanib MTD = 1000 mg BID 
DLTs = hematologic, GI, renal, and 
hepatic 
6-month PFS = 25% 
NA 36 
Imatinib II Recurrent 39 6-month PFS = 24% NA 37 
Imatinib II Recurrent 50/55 MTD = 800 mg/day 
two PR, six SD (GBM) 
zero PR, five SD (AG) 
6-month PFS = 3% (GBM), 10% (AG) 
NA 38 
Imatinib II Recurrent 112 PR = five (three GBM) 
6-month PFS rate = 16% (95% CI, 
8.0% to 34.0%) in GBM 
NA 39 
Imatinib II Recurrent 231 Radiographic response rate = 3.4% 
6-month PFS = 10.6% 
NA 40 
Hydroxyurea +/- 
Imatinib 
III Recurrent 240 Median PFS = 6 weeks (both arms) 
6-month PFS = 7% (combination) 
NA 41 
 36
Lapatinib I/II Recurrent 7 (phI) 
17 (phII) 
DLT = none, efficacy (SD = four, PD = 
13) 
None 42 
Sorafenib+erlotinib I/II Recurrent 17 (phI) 
19 (phII) 
6-month PFS = 16% NR 43 
Talampanel II Recurrent 30 (22 
GBM) 
6-month PFS = 4.6% NA 44 
Vorinostat II Recurrent 66 6-month PFS = 15.2% 
OS 5.7 months 
NA 45 
Temsirolimus II Recurrent 65 6-month PFS = 7.8% 
OS 5.7 months 
p70S6 kinase 46 
 
AG, anaplastic glioma; BID, twice daily; CCNU, lomustine; CI, confidence interval; cPR, confirmed partial response; CR,= complete response; 
GI, gastrointestinal; DLT, dose-limiting toxicities; EGFR, epidermal growth factor receptor; GBM, glioblastoma multiforme; MG, malignant 
glioma; MGMT, methyl guanine methyltransferase; MTD, maximum tolerated dose; NA, not available; NR, not recorded; OR, objective 
response; OS, overall survival; ph, phase; PD, progressive disease; PFS, progression-free survival; PR, partial response; PTEN, phosphatase 
and tensin homolog; RT, radiotherapy; SD, stable disease; TMZ, temozolomide.
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Table 3. Ongoing clinical trials of targeted therapies 
 
Treatment Phase Primary/recurrent 
disease 
Patients 
(n) 
Primary outcomes Trial 
identifier 
APG101+RT II Recurrent 83 6-month PFS NCT01071837 
BIBW2992+RT+TMZ I Primary 38 NA NCT00977431 
BIBW2992+TMZ I/II Recurrent 140 NA NCT00727506 
BIBW2992 II Recurrent 60 NA NCT00875433 
BSI-201 I/II Primary 100 Safety, OS NCT00687765 
Bevacizumab+Dasatinib I/II Recurrent 183 Safety, PFS, OS NCT00892177 
Bevacizumab+TMZ+RT vs TMZ+RT III Primary 942 PFS, OS NCT00884741 
Bevacizumab+TMZ+RT vs TMZ+RT III Primary 920 PFS, OS NCT00943826 
Cediranib+TMZ I/II Primary 80 Safety, PFS NCT00662506 
Cediranib I Any 55 MTD, DLT NCT00326664 
Cediranib+bevacizumab I Recurrent 51 MTD, PK, toxicity NCT00458731 
Cediranib+cilengitide I Recurrent 52 Safety NCT00979862 
Cetuximab+bevacizumab+irinotecan II Recurrent 32 NA NCT00463073 
 39
Cilengitide+TMZ+RT vs TMZ+RT II Primary 177 PFS NCT01062425 
Cilengitide+TMZ+RT vs TMZ+RT III Primary 504 OS NCT00689221 
Dasatinib+TMZ+RT vs TMZ+RT I/II Primary 217 Safety/OS NCT00869401 
Dasatinib+TMZ+RT I/II Primary 72 MTD/OS NCT00895960 
Dasatinib+erlotinib I Recurrent 48 MTD, DLT NCT00609999 
Dasatinib+CCNU I/II Recurrent 108 Safety/PFS NCT00948389 
Dasatinib II Recurrent 113 6-month PFS NCT00423735 
Erlotinib+TMZ+RT II Primary 30 6-month PFS NCT00274833 
Erlotinib+sirolimus I/II Recurrent 99 NA NCT00509431 
Erlotinib+sirolimus II Recurrent 20 6-month PFS NCT00672243 
Erlotinib+sorafenib II Recurrent 56 OS NCT00445588 
Everolimus+TMZ+RT I/II Primary 108 MTD/OS NCT00553150 
Imatinib+TMZ I Any 40 Safety, PK, antitumor 
activity 
NCT00354068 
Imatinib+TMZ I Recurrent 40 Safety, PK, antitumor 
activity 
NCT00354068 
Imatinib+hydroxyurea I Recurrent 48 MTD, DLT NCT00613054 
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Imatinib+hydroxyurea I Recurrent 72 MTD, DLT NCT00613132 
Imatinib II Recurrent 77 6-month PFS NCT00039364 
Imatinib+hydroxyurea II Recurrent 21 6-month PFS NCT00611234 
Imatinib+hydroxyurea II Recurrent 64 12-month PFS NCT00615927 
Lapatinib+pazopanib I/II Recurrent 105 NA NCT00350727 
Lapatinib II Recurrent 44 NA NCT00103129 
Sorafenib I Primary 18 NA NCT00884416 
Sorafenib+RT+TMZ I/II Primary 51 NA NCT00734526 
TMZTMZ+RT+sorafenib II Primary 46 NA NCT00544817 
Sorafenib I Recurrent 36 NA NCT00093613 
Sorafenib+temsirolimus I/II Recurrent 141 NA NCT00329719 
Sorafenib II Recurrent 32 NA NCT00597493 
Sorafenib+bevacizumab II Recurrent 53 NA NCT00621686 
Tandutinib I/II Any 85 MTD, safety, response NCT00379080 
Tandutinib+bevacizumab II Any 80 6-month PFS NCT00667394 
Vandetanib+TMZ I/II Primary 114 NA NCT00441142 
Vandetanib+etoposide I Recurrent 48 NA NCT00613223 
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Vandetanib+imatinib+hydroxyurea  I Recurrent 48 NA NCT00613054 
Vandetanib+sirolimus I Recurrent 33 NA NCT00821080 
Vandetanib I/II Recurrent 94 NA NCT00293566 
Vandetanib+carboplatin vs 
vandetanibcarboplatin 
II Recurrent 128 NA NCT00995007 
Vorinostat II Recurrent 94 PFS NCT00238303 
Vorinostat+RT+TMZ I/II Primary 132 Safety/OS NCT00731731 
Vorinostat+bevacizumab+irinotecan I Recurrent 21 NA NCT00762255 
Vandetanib+bevacizumab vs bevacizumab I/II Recurrent 108 Safety/PFS NCT01266031 
Vorinostat+TMZ I/II Recurrent 52 Safety/PFS NCT00939991 
Vorinostat+TMZ I Recurrent 77 NA NCT00268385 
Vorinostat+Bortezomib II Recurrent 68 PFS NCT00641706 
XL184+RT+TMZ I Primary 85 Safety NCT00960492 
XL765+TMZ I Maintainance 80 Safety NCT00704080 
 
CCNU, lomustine; DLT, dose-limiting toxicities; MTD, maximum tolerated dose; NA, not available; OS, overall survival; PFS, progression-free 
survival; PK, pharmacokinetics; RT, radiotherapy; TMZ, temozolomide. 




